Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

7.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.6K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
958
Hyperglycemia01:29

Hyperglycemia

34
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placental plasminogen activator inhibitor 1 is induced by platelet-derived TGF-β independently of TGF-β receptor 3 and is upregulated in preeclampsia.

Molecular human reproduction·2026
Same author

Effect of green mediterranean diet on serum folate and its interaction with genetic variation in folate metabolism: The DIRECT PLUS 18-month dietary randomized controlled trial.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials.

Circulation·2026
Same author

Endothelial dysfunction and metabolic biomarkers in post-COVID-19 syndrome.

Scientific reports·2026
Same author

Obesity-Related Coagulation Activation in Adolescents and Children: A Systematic Review and Meta-Analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife.

Nature communications·2026

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.1K

Decrease of serum S100B during an oral glucose tolerance test correlates inversely with the insulin response.

Johann Steiner1, Hans-Gert Bernstein2, Kolja Schiltz1

  • 1Department of Psychiatry, University of Magdeburg, Magdeburg, Germany; Center for Behavioral Brain Sciences, Magdeburg, Germany.

Psychoneuroendocrinology
|November 27, 2013
PubMed
Summary
This summary is machine-generated.

Serum S100B levels decreased after glucose intake in healthy individuals. This reduction was inversely linked to insulin and C-peptide levels, suggesting insulin may regulate S100B release. Standardized blood collection is recommended for studies.

Keywords:
AdipocytesAstrocytesHepatocytesInsulinOligodendrocytesOral glucose toleranceS100B

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.1K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

10.5K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.1K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.1K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

10.5K

Area of Science:

  • Biochemistry
  • Endocrinology
  • Neuroscience

Background:

  • S100B serum levels are linked to glial pathology and brain damage.
  • S100B expression occurs outside the nervous system, indicating non-brain origins.
  • Insulin may down-regulate S100B secretion in adipocytes, while stress and fasting up-regulate it.

Purpose of the Study:

  • To investigate dynamic changes in S100B serum levels following an oral glucose tolerance test (OGTT) in healthy subjects.
  • To explore the relationship between S100B levels and other metabolic markers during glucose challenge.

Main Methods:

  • Seventeen healthy adults underwent an OGTT with 75g glucose after an overnight fast.
  • Serum levels of S100B, glucose, free fatty acids, insulin, C-peptide, and cortisol were measured at 0, 1, and 2 hours.
  • Statistical analysis was used to assess changes and correlations between variables.

Main Results:

  • Mean S100B concentrations decreased by approximately 20% within the first hour post-glucose ingestion (P<0.001).
  • The decrease in S100B was not associated with cortisol levels.
  • Serum S100B reduction at 1 hour correlated inversely with changes in insulin (r = -0.484, P=0.049) and C-peptide (r = -0.570, P = 0.017).

Conclusions:

  • The study suggests an inverse correlation between insulin secretion and S100B release following a standardized OGTT.
  • Further research is needed to confirm insulin-regulated S100B release in vivo.
  • Standardized blood collection protocols, such as overnight fasting, are crucial for comparable clinical studies on S100B serum levels.